Provider review
Synergy Rx Review: Four Peptides at One Price, and a Headline It Cannot Support
Synergy Rx prices almost its entire longevity range identically: NAD+, sermorelin, glutathione and PT-141 are each "Starting at $275". Four molecules, four different evidence bases, one number. Its homepage headline is "The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week" — the word proven, the STEP 1 figure and a rate of loss, with no citation anywhere.
Synergy Rx has one genuinely good disclosure and builds nothing on top of it. Its FAQ names four pharmacies with phone numbers and two doctors you can verify in the federal registry — and then its Terms, the document a careful reader would actually open, name no pharmacy, belong substantially to a different company, and contain not one occurrence of the words subscription or cancel. Its longevity range prices four unrelated molecules at exactly $275 with no description of any of them: sermorelin, whose randomized trials are 1986-2005 pituitary pharmacology and test nothing sold here; injected glutathione, whose one randomized trial of that route was in Parkinson's disease and was null; injected NAD+, which has no completed trial; and PT-141, which has real phase 3 evidence in premenopausal women and an approved label stating it is not indicated in men. Over all of it sits a headline promising "The Proven Way to lose 15% of your body weight fast" — proven by nothing the site cites, 15% borrowed from a 68-week trial of a different product, and fast being the one thing that trial specifically was not.
Worth trusting if
- You want the dispensing pharmacy named before you buy, because the FAQ lists four of them with phone numbers and working websites.
- You want to weigh compounded against brand-name, because the weight loss tab prices both, with Ozempic at roughly half what Wegovy and Mounjaro cost.
- You intend to check the prescriber yourself, because both clinicians are named and both resolve in the federal registry.
Be skeptical if
- You need cancellation terms in writing, because the words subscription and cancel appear zero times in the terms.
- You are buying the sermorelin, NAD+, glutathione or PT-141, because all four carry the identical figure and none has a description on the page.
- You want the headline checked, because nothing on the site cites a source for losing 15% of your body weight fast.
Approved + compounded
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.synergyrx.co. A link is not a recommendation to take anything.
Provenance
What Synergy Rx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Wegovy® — $947, read card by card in a browser on 2026-08-26 from the Weight Loss tab — 4.8 times the compounded semaglutide injection listed on the same tab.
- Mounjaro® — $947, read card by card in a browser on 2026-08-26 from the Weight Loss tab — 2.7 times the compounded tirzepatide injection on the same tab, and the same figure Synergy lists for Wegovy.
- Ozempic® — $499, read card by card in a browser on 2026-08-26 from the Weight Loss tab — the cheapest brand row, about half what Synergy lists for Wegovy and Mounjaro, and 2.5 times the compounded semaglutide injection.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin Injection — "Starting at $275" — a floor, not a price. Synergy publishes no dose, no supply length and no billing interval.
- NAD+ Injection — "Starting at $275" — identical to sermorelin, glutathione and PT-141.
- Glutathione Injection — "Starting at $275".
- PT-141 — "Starting at $275".
- Compounded semaglutide — $199 — read in-browser on 2026-08-10 from the Weight Loss tab of the products page. The page opens on the Longevity tab, so the GLP-1 figures only appear after a click.
- Compounded tirzepatide — $349, and oral semaglutide $299 — both read in-browser on 2026-08-10 from the WEIGHT LOSS tab.
- Compounded Semaglutide Oral Dissolving Tablet — $299, read card by card in a browser on 2026-08-26 from the Weight Loss tab. The Longevity tab the page opens on does not show it.
- Compounded Tirzepatide Oral Dissolving Tablet — $399, read card by card in a browser on 2026-08-26 from the Weight Loss tab — the most expensive of the four compounded rows.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
7
Molecules with human evidence
For the use they are sold for, out of 11 products reviewed here. The evidence belongs to the molecule, not to Synergy Rx.
11
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Synergy Rx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Sermorelin InjectionSermorelin · Compounded (503A)No trial supports this claim
“Sermorelin Injection — Starting at $275. […] Find the right medication with the confidence that comes from knowing it is doctor-approved and budget-friendly. […] Certified Medication.”
Read on the Synergy Rx site, August 2026
No trial for this use
What the trials show for Sermorelin
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six searches were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies returned are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified diagnostic "GHRH". In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO carry the randomized-controlled-trial or clinical-trial publication type. The searches discriminate: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
Synergy publishes no description of sermorelin at all — no mechanism, no indication, no benefit, no contraindication — so there is no sentence to hold against the literature, and no trial to hold it against either: no registered study names sermorelin as an intervention under any of six searches. What the site does assert, across the whole range, is that its medication is "doctor-approved" and "Certified" — neither of which is a term with a meaning a reader can check. Note the pricing: sermorelin is $275, exactly the same as NAD+, glutathione and PT-141, three molecules with completely different evidence bases and manufacturing profiles.1,2
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+ Injection — Starting at $275. […] Trusted by experts, priced for you. Find the right medication with the confidence that comes from knowing it is doctor-approved and budget-friendly.”
Read on the Synergy Rx site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
As with sermorelin, no description is published — the product exists as a name, a price and a "Get Started" button. Injected NAD+ has no completed randomized human trial behind it. The only assertions attached are "Trusted by experts" and "doctor-approved", which name no expert and describe no approval that exists: FDA approves no compounded preparation, and a prescriber's willingness to write a prescription is not an approval of a product.3
Glutathione InjectionGlutathione · Compounded (503A)No trial supports this claim
“Glutathione Injection — Starting at $275. […] doctor-approved and budget-friendly.”
Read on the Synergy Rx site, August 2026
Phase 1 only
What the trials show for Glutathione
- NCT00889538 — Phase 1/2, completed, n=24. Twenty-four children, glutathione given as a drug alongside vitamin C and cysteine, in autism with severe behavior. The only completed registry study that administers injected glutathione itself, and it is not about anything this product is sold for.
The entire human record for injected glutathione in adults is two phase 1 studies enrolling ten and sixteen people, both about oxidative stress in HIV infection. A ClinicalTrials.gov search returning 200 glutathione intervention records yields only four involving an injected or intravenous route, the other two being a neonatal cysteine-supplementation study and a lymphoma chemotherapy trial. Synergy states no indication, so there is no claim to check — and nothing in that literature supports a wellness or longevity purchase at $275.4
PT-141Bremelanotide (PT-141) · Compounded (503A)No trial supports this claim
“PT-141 — Starting at $275. […] Sexual Health. […] doctor-approved and budget-friendly.”
Read on the Synergy Rx site, August 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Bremelanotide in premenopausal women with hypoactive sexual desire disorder. No male participants.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The second registration trial, same population. The resulting approval is for premenopausal women only.
PT-141 is bremelanotide, and it is the one molecule in Synergy's longevity range with phase 3 evidence — 723 and 714 participants, all premenopausal women with hypoactive sexual desire disorder. The approved product containing it is Vyleesi, whose label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men" and "VYLEESI is not indicated to enhance sexual performance." Synergy lists PT-141 under Sexual Health with no indication, no population and no mention of either limitation, at the same $275 as three unrelated molecules. There is real evidence here; it is for a population and a purpose the product page does not identify.5,6
Compounded semaglutideSemaglutide · Compounded (503A)Claim reaches past the trials
“The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized. […] Join 50,000+ SynergyRx patients.”
Read on the Synergy Rx site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product over 68 weeks; about 14.9% weight loss from baseline against 2.4% on placebo. No compounded semaglutide from any seller has been through a registered trial.
Four words do the damage. "PROVEN" — Synergy cites nothing, anywhere on the site, and what it dispenses is a compounded preparation that has never been in a registered trial. "15%" is STEP 1's figure, borrowed without attribution and attached to Synergy's own service. "FAST" is the opposite of what STEP 1 describes: that result took 68 weeks. And "EFFORTLESS" is contradicted by the trial itself, in which every participant received structured lifestyle intervention alongside the drug. "Lose 1-2lbs per week" is a rate claim with nothing behind it. The molecule genuinely works — that is not in question — but every qualifier attached to it here is wrong in the direction that flatters the sale.7
Compounded tirzepatideTirzepatide · Compounded (503A)Claim reaches past the trials
“The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Read on the Synergy Rx site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product at the highest tolerated dose over 72 weeks.
The same site-wide headline covers tirzepatide, and it fits even less well: the 15% figure belongs to semaglutide's STEP 1, while SURMOUNT-1 reported roughly 20% for tirzepatide over 72 weeks. So the headline simultaneously under-describes one molecule and over-qualifies both, with "proven", "fast" and "effortless" attached to results that took a year and a half under trial conditions. Synergy makes no molecule-specific claim for tirzepatide anywhere.8
Compounded Semaglutide Oral Dissolving TabletSemaglutide · Compounded (503A)No trial supports this claim
“Starting at $299 — Compounded Semaglutide Oral Dissolving Tablet. […] The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Read on the Synergy Rx site, August 2026
No trial for this use
What the trials show for Semaglutide
As of 26 August 2026, ClinicalTrials.gov v2 holds no study testing semaglutide as an orally dissolving or sublingual tablet. Four searches were run against the intervention field — "sublingual semaglutide", "orally disintegrating semaglutide", "orally disintegrating tablet semaglutide" and "buccal semaglutide" — with no status filter, so a record at any stage would have surfaced. Three returned zero. "Sublingual semaglutide" returned two records and neither is one: NCT06301191 is a subcutaneous semaglutide study at a Greek hospital, and NCT07092605 is an early-phase-1 study of a "Sublingual GLP1" that is enrolling by invitation, has not reported, is sponsored by a seller of the format, and does not name its molecule in the registry at all. The searches discriminate: in the same pass a bare "semaglutide" query returned 339 completed studies and "oral semaglutide" returned 197 records of any status. Every one of those oral records tests the swallowed SNAC tablet, which is a different dosage form — see the note below.
Semaglutide taken by mouth has a real and large evidence base — and none of it tested a tablet that dissolves in the mouth. The approved oral product is Rybelsus, a tablet swallowed whole with an absorption enhancer that carries the drug across the stomach lining, and it was registered on the PIONEER program: PIONEER 1 (NCT02906930, phase 3, completed, 703 participants) measured HbA1c in type 2 diabetes. The obesity trials of that same swallowed tablet are the OASIS studies. A tablet designed to dissolve under the tongue is asking a 4-kilodalton peptide to cross a different membrane, without the absorption enhancer that makes the swallowed version work, and no registered study has tested whether it does. That is the whole question for a molecule this size, and Synergy publishes no bioavailability data, no pharmacokinetic result and no study of any kind for it — only the site-wide headline, whose 15% belongs to a 68-week trial of a once-weekly injection.12,13
Compounded Tirzepatide Oral Dissolving TabletTirzepatide · Compounded (503A)No trial supports this claim
“Starting at $399 — Compounded Tirzepatide Oral Dissolving Tablet. […] The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Read on the Synergy Rx site, August 2026
No trial for this use
What the trials show for Tirzepatide
As of 26 August 2026, ClinicalTrials.gov v2 holds no record of tirzepatide by any route other than subcutaneous injection. Intervention searches for "sublingual tirzepatide" and "orally disintegrating tirzepatide", run with no status filter so that a planned or recruiting study would appear, each returned zero. The control fired in the same pass: a bare "tirzepatide" intervention query returned 276 records of any status and 91 completed studies, and the registered arms describe the drug as administered subcutaneously once a week. There is no oral tirzepatide in development under that name — the oral incretin drug in late-stage trials, orforglipron (50 records), is a different molecule, a small-molecule GLP-1 agonist rather than a peptide, and nothing in its program transfers to a compounded tirzepatide tablet.
This is the emptiest row on the page and the second most expensive of the compounded four. Tirzepatide has been tested in humans a great deal, and every one of those tests put it under the skin. Nothing in the registry asks whether the molecule survives the mouth, and Synergy publishes no answer of its own — no bioavailability figure, no pharmacokinetic curve, no study name. Route is not a packaging detail for a peptide of this size; it is the question of whether any drug reaches the blood at all. So the headline's "proven" is doing more work here than anywhere else on the site: the injection it is borrowed from is not the product being sold, and the format being sold has never been measured.12
Wegovy®Semaglutide · FDA-approvedClaim reaches past the trials
“Starting at $947 — Wegovy®. […] The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Read on the Synergy Rx site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548987 STEP 4 — Phase 3, completed, n=902. Registered as "Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity", with the primary outcome "Change From Randomisation to Week 68 in Body Weight (%)". Conditions: obesity and metabolism and nutrition disorder. Read from the registry on 2026-08-26.
- NCT03611582 STEP 3 — Phase 3, completed, n=611. Registered as semaglutide 2.4 mg once-weekly "as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity", primary outcome "Change in Body Weight (%)". The design is the answer to "effortless": the trial pairs the drug with intensive behavioral therapy by construction. Read from the registry on 2026-08-26.
This is the one row where the headline's central word survives. Wegovy is semaglutide 2.4 mg approved for weight management, and the STEP program is a set of phase 3 obesity trials of exactly that product measuring exactly that outcome — so unlike the compounded rows, the thing in the box has been through the trials the number comes from. "Proven" is defensible here and nowhere else on this tab. Two of the four words still fail, and they fail for the same reasons: STEP 4's primary endpoint is body weight at week 68, so "fast" describes a sixteen-month result, and STEP 3 is registered as the same dose "as Adjunct to Intensive Behavioural Therapy", so "effortless" names the one condition under which the number was not obtained. What Synergy never says is that it is selling the trialed product beside a compounded copy of the same molecule for a fraction of the price, and that only one of the two has ever been in a trial.9
Mounjaro®Tirzepatide · FDA-approvedClaim reaches past the trials
“Starting at $947 — Mounjaro®. […] The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Read on the Synergy Rx site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT03987919 SURPASS-2 — Phase 3, completed, n=1,879. Tirzepatide versus semaglutide once weekly as add-on to metformin in participants with type 2 diabetes. Condition: type 2 diabetes. Primary outcome: change from baseline in HbA1c. Read from the registry on 2026-08-26.
- NCT03954834 SURPASS-1 — Phase 3, completed, n=478. Three tirzepatide doses versus placebo in type 2 diabetes inadequately controlled with diet and exercise. Primary outcome: change from baseline in HbA1c. Every arm is a subcutaneous injection. Read from the registry on 2026-08-26.
Mounjaro is tirzepatide approved for type 2 diabetes, and the program behind that approval is SURPASS — glycemic-control trials whose registered primary outcome is HbA1c, not body weight. The obesity trials of tirzepatide belong to a different program and a different product, which Synergy does not sell and this review does not name as though it did. So the headline over this card is borrowing twice: a percentage from semaglutide's obesity program, attached to a diabetes drug whose own pivotal trials measured blood sugar. The evidence for Mounjaro is genuinely large and genuinely good — 1,879 participants in SURPASS-2 alone — it is simply evidence for something the page is not selling it as. Nothing on the card says the approved indication is diabetes.11
Ozempic®Semaglutide · FDA-approvedClaim reaches past the trials
“Starting at $499 — Ozempic®. […] The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Read on the Synergy Rx site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT02054897 SUSTAIN 1 — Phase 3, completed, n=388. Semaglutide once-weekly versus placebo in drug-naive subjects with type 2 diabetes. Primary outcome: change in HbA1c. Read from the registry on 2026-08-26.
- NCT01720446 SUSTAIN 6 — Phase 3, completed, n=3,297. The cardiovascular outcomes trial in type 2 diabetes, and by far the largest study behind either brand on this tab. Primary outcome: time from randomization to first major adverse cardiovascular event. Read from the registry on 2026-08-26.
Ozempic is semaglutide approved for type 2 diabetes, and its pivotal program is SUSTAIN, whose registered primary outcomes are HbA1c and cardiovascular events. The 15% on Synergy's headline comes from the STEP program, which tested a higher-dose semaglutide product approved for weight management — a different product with a different label, sold on this same tab under a different name and at roughly twice the price. Both are semaglutide; they are not interchangeable evidence, and a reader looking at the cheaper of the two brand rows has no way to learn from this page that its approval is for diabetes. That Ozempic costs about half what Wegovy does here is exactly the kind of gap that pushes a weight-loss buyer toward the diabetes product, and the page says nothing about the difference.10
Dispensing chain
Who actually fills your prescription
- Belmar Pharmacy
- Strive Pharmacy
- Epiq Scripts
- Casa Pharma Rx
Read the full account
Synergy names four dispensing pharmacies with phone numbers and websites in its homepage FAQ — "Belmar Pharmacy | Phone: 800-525-9473 | belmarpharmasolutions.com; Strive Pharmacy | Phone: 855-405-5993 | strivepharmacy.com; Epiq Scripts | Phone: 833-654-3553 | epiqscripts.com; Casa Pharma Rx | Phone: 877-937-6868 | casapharmarx.com" — and two named, licensed prescribing clinicians: Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD, both through Lion MD. That is a real, checkable disclosure and it is the best thing on this site. It exists in one document only, though. Synergy's Terms & Conditions name no pharmacy at all, so anyone who reads the Terms — the natural place to look — would wrongly conclude this company names none. Which of the four fills a given order is not disclosed. Belmar's own FDA letter of 31 March 2023 was closed out on 30 October 2023, and belongs to the pharmacy rather than to Synergy. Synergy shares its technical backend with another brand in this wave — the same payment and verification infrastructure, under distinct organization IDs and seals. Common ownership is not proven and is not asserted; a shared white-label platform is not grounds to treat the brands as duplicates.
Read on the Synergy Rx site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product. The quality vocabulary is a list of adjectives that cannot be checked: "Certified Medication", "doctor-approved", "Trusted by experts", "Licensed Providers". None of those is a standard, and "doctor-approved" in particular describes a prescriber's willingness to write a prescription rather than any approval of a product — FDA approves no compounded preparation. What Synergy does publish, and what genuinely helps, is the pharmacy list: four named facilities with phone numbers, which at least gives a patient somebody to ask for a lot record. No study, trial identifier or publication is cited anywhere on the site, for any product — including for the two GLP-1 molecules whose phase 3 programs its own headline is borrowing a number from.
Read on the Synergy Rx site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
"All 50 U.S. states" by the FAQ; "certain states" by the Terms, with no list published
Read the full licensing claim
Synergy's two published answers do not agree. Its homepage FAQ: "Is this service available in all states? Our telemedicine services are available in all 50 U.S. states, subject to each state's telehealth and prescribing regulations." Its Terms, section V: "The Services are currently available to individuals located in certain states. To see the list of current states, please contact customer service at info@synergyrx.co." No list is published anywhere, so no excluded state is recorded here — naming exclusions would mean inventing them, not because none exist. The corporate structure is unusual and worth reading in full: "The terms 'we', 'us', 'our' and 'CareGLP' refer to CareGLP, owned by SynergyRx, a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609" — a Delaware corporation at a Wyoming address — with disputes to be resolved "exclusively in the U.S. District Court for Georgia, or a state court located in Fulton County, Georgia". Three states for one company, and the operating brand named in the agreement is a different one from the one on the storefront. The Terms are dated "Last updated: January 1, 2024" and contain ZERO occurrences of "subscription" and ZERO of "cancel", so a patient buying a recurring medication has no published cancellation terms at all.
Read on the Synergy Rx site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Synergy Rx
We went through Synergy Rx’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Open the products page, which loads on the Longevity tab, and click Weight Loss before any GLP-1 price appears.
- Press Get Started, which opens a consultation form on the same site.
- Give your height and weight, and watch it compute a BMI as you go.
- Give your goal weight.
- Say what you have tried before: exercise, dieting, supplements, intermittent fasting, or none of these.
- Say whether you are male or female.
- Say your main reason for looking at a GLP-1: health, confidence, energy, or other.
- Say whether you are already taking a GLP-1.
- Check any of five serious conditions — end-stage kidney disease, cirrhosis, suicidal thoughts, cancer, transplant — or none of these.
- Check any of a second list — gallbladder disease, hypertension, seizures, glaucoma, sleep apnea, diabetes, retinopathy — or none of these.
- Say whether you have had prior weight loss surgery.
- Say whether you currently take any medications.
- Give your date of birth.
- Give a first name, last name, email address and phone number, and attest that your answers are true and complete, to finish.
- The prices are published, but the products page opens on Longevity. Until you click the Weight Loss tab, the page shows five peptides at one flat figure and no GLP-1 at all.
- On that tab the compounded semaglutide injection is the cheapest row and the oral dissolving tablets sit above it, with tirzepatide's tablet at $399. The brand-name rows are far higher again: Wegovy and Mounjaro at $947 each, Ozempic at $499.
- Twelve screens of intake go by without a number. The FAQ is explicit that pricing is provided after your consultation, which it calls transparent pricing.
- The last screen prints a projection before you have typed a name: your BMI, your goal weight within 54 weeks, and a claim that you have a 94 percent chance of successful treatment if qualified. Nothing on the site says where that figure comes from.
- That same screen wants a phone number and an attestation that every answer is true and complete. We stopped there rather than sign invented answers over to a clinician.
- There is no support phone number anywhere on the site. The contact page is a message form, and the only address published, info@synergyrx.co, sits in the terms rather than on the contact page.
Synergy Rx support
- info@synergyrx.co
Assessment
What holds up, and what does not
- Its FAQ names four dispensing pharmacies with phone numbers and working websites — Belmar, Strive, Epiq Scripts and Casa Pharma Rx.
- Two prescribing clinicians are named and licensed — Dr. Ana Lisa Carr and Dr. Kelly Tenbrink — both verifiable in the federal NPPES registry.
- Peptide prices are on the page itself, visible without an intake — five products with figures, which several competitors will not show before collecting a phone number.
Show 3 more
- The eligibility criteria are stated concretely: "A BMI of 30 or higher, or a BMI of 27+ with at least one weight-related condition", which matches the criteria the trials used.
- It acknowledges that its GLP-1s are compounded formulations "through licensed U.S. compounding pharmacies that comply with FDA and state regulations" rather than implying they are the branded drug.
- No FDA warning letter for SynergyRx or CareGLP as of 10 August 2026.
- "The Proven Way to lose 15% of your body weight fast!" — nothing is cited anywhere on the site, and the 15% belongs to STEP 1, a 68-week trial of the approved product.
- "Fast" and "effortless" both contradict that trial, which took 68 weeks and gave every participant structured lifestyle support alongside the drug.
- "Lose 1-2lbs per week" is a rate-of-loss claim with no source.
Show 14 more
- Four unrelated molecules — sermorelin, NAD+, glutathione and PT-141 — are all priced at exactly $275, and all five longevity products are "Starting at" floors with no dose, supply length or billing interval published.
- No description is published for any peptide: no mechanism, indication, benefit or contraindication for sermorelin, NAD+, glutathione or PT-141.
- PT-141 is sold under Sexual Health with no indication stated, when the approved product's label says it is not indicated in men and not indicated to enhance sexual performance.
- The Terms name no pharmacy, so the disclosure exists in exactly one document and the natural place to look contradicts it by silence.
- The Terms are substantially another brand's: "CareGLP" appears 68 times against 56 for "SynergyRx", and the agreement opens by describing CareGLP's scope rather than Synergy's.
- They contain zero occurrences of "subscription" and zero of "cancel" — no published cancellation terms for a recurring medication.
- "Available in all 50 U.S. states" in the FAQ against "available to individuals located in certain states" in the Terms, with no list published in either.
- Three jurisdictions for one company: a Delaware corporation, at a Wyoming address, with disputes venued in Fulton County, Georgia.
- Weight-loss prices are behind a tab that defaults to Longevity, so you can look at the products page and never see them.
- The two oral dissolving tablets have no route evidence at all: no registered study tests semaglutide or tirzepatide as a tablet dissolved in the mouth, and the tirzepatide one is the most expensive of the four compounded rows.
- Ozempic and Mounjaro are approved for type 2 diabetes, and their pivotal programs measured blood sugar — but they sit under a weight-loss headline that says nothing about the difference, with Ozempic the cheapest brand row at $499.
- The same molecule is sold twice at 4.8 times the difference — Wegovy at $947 beside compounded semaglutide at $199 — with no explanation on the page of what the extra buys.
- On the storefront the price is printed above the product name rather than below it, so a reader skimming the tab can attach a figure to the wrong row.
- No certificate of analysis, lot number or laboratory result is published, and no study is cited anywhere for any product.
Verdict
The bottom line
One price across four unrelated molecules tells you the number was set by marketing rather than by anything about the products. Synergy does one thing genuinely well — its FAQ names four dispensing pharmacies with phone numbers and two named, licensed prescribing doctors — so use that, and ask where the word "proven" on the homepage comes from, because no page on the site says.
Opens www.synergyrx.co. A link is not a recommendation to take anything.
The prices are there — behind a tab
Synergy's products page has category tabs: Longevity, Hair, Sexual Health, Skin, Weight Loss. It opens on Longevity. One click on Weight Loss shows semaglutide at $199, tirzepatide at $349 and oral semaglutide at $299 — all re-checked in a browser on 10 August 2026.
Nothing tells you the other tabs exist. The page you land on already looks complete: five Longevity products, real prices. The GLP-1 figures are published — you just have to click for them — and a visitor scanning for a weight-loss price can easily leave believing there isn't one.
Full analysis — 9 more sectionsFour molecules, one price · What the registries hold for those four · "The Proven Way to lose 15% of your body weight fast!" · Seven products under one headline · One molecule, two prices, 4.8× apart · The brand rows are not all weight-loss drugs · The two tablets have no route evidence at all · Two documents, two companies, three states · What this means if you are buying
Four molecules, one price
Synergy's longevity range, as its own page renders it:
| Product | Price |
|---|---|
| NAD+ Injection | Starting at $275 |
| Sermorelin Injection | Starting at $275 |
| Glutathione Injection | Starting at $275 |
| PT-141 | Starting at $275 |
| B12 Methylcobalamin | Starting at $109 |
Four different molecules at an identical price. They have nothing in common. Sermorelin is a growth-hormone-releasing peptide. NAD+ is a coenzyme. Glutathione is a tripeptide antioxidant. PT-141 is a melanocortin receptor agonist for sexual desire. Their evidence bases, their manufacturing considerations and their reasons for being taken are entirely unrelated, and they cost the same.
Every one is "Starting at", which is a floor rather than a price, and Synergy publishes no dose, no supply length and no billing interval for any of them.
It also publishes no description of any of them. There is no mechanism, no indication, no benefit, no contraindication, no side-effect list. Each product is a name, a number and a "Get Started" button. The only claims attached are site-wide adjectives: "doctor-approved", "Certified Medication", "Trusted by experts".
"Doctor-approved" is worth pausing on. It describes a prescriber's willingness to write a prescription. It is not an approval of a product, and FDA approves no compounded preparation at all.
What the registries hold for those four
Sermorelin has nothing. A ClinicalTrials.gov search returns no interventional record naming it as the intervention, across six searches including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name, plus a free-text pass over every field. 1 The 27 studies returned are other molecules — mostly tesamorelin and GHRH(1-44). PubMed holds 24 records mentioning it and none with a randomized-trial publication type. 2 Controls run in the same pass: tirzepatide 158 registry records and 126 papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
Injected NAD+ has no completed randomized human trial supporting a restoration-of-function claim. 3 The real literature is about oral precursors — different molecules, different route.
Injected glutathione has almost nothing: of 200 glutathione intervention records, four involve an injected or intravenous route, and the two studying it in adults are phase 1 trials of ten and sixteen people, both about oxidative stress in HIV infection. 4
PT-141 is the interesting one, because it has the most evidence and the widest gap. Bremelanotide has two phase 3 trials, RECONNECT 1 and 2, enrolling 723 and 714 participants — all premenopausal women with hypoactive sexual desire disorder. 5 6 The approved product is Vyleesi, and its label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance."
Synergy lists PT-141 under "Sexual Health" with no indication, no population and no mention of either sentence.
"The Proven Way to lose 15% of your body weight fast!"
That is Synergy's homepage headline, beneath "Medically supervised, effortless weight loss that's personalized" and above "Lose 1-2lbs per week."
Four words in it are doing work the site cannot support.
"Proven." Synergy cites nothing. Not a trial, not a PubMed ID, not a study name — anywhere on the site, for any product. And what it dispenses is a compounded preparation, which has never been through a registered trial from any seller.
"15%." That is STEP 1's number: roughly 14.9% weight loss from baseline against 2.4% on placebo. 7 It is real, and it belongs to the approved 2.4 mg product, not to Synergy's compounded version. It is borrowed without attribution and attached to Synergy's own service.
"Fast." STEP 1 took 68 weeks to produce that result. Sixteen months is not fast, and describing it that way inverts the single most important expectation a patient should start with.
"Effortless." In STEP 1, every participant — treatment and placebo alike — received structured lifestyle intervention: a reduced-calorie diet and increased physical activity, with monthly counseling. The 15% figure is what the drug added on top of that effort. "Effortless" describes the one condition under which the number was not obtained.
"Lose 1-2lbs per week" is a rate claim with no source at all.
The underlying molecules work. Semaglutide and tirzepatide have large, genuine phase 3 programs. 7 8 Every qualifier Synergy attaches to them points in the direction that flatters the sale.
Seven products under one headline
That headline sits above the whole Weight Loss tab, and the tab is not three rows. It is seven, read card by card in a browser on 26 August 2026:
| Product | Price |
|---|---|
| Compounded Semaglutide | Starting at $199 |
| Compounded Tirzepatide | Starting at $349 |
| Compounded Semaglutide Oral Dissolving Tablet | Starting at $299 |
| Compounded Tirzepatide Oral Dissolving Tablet | Starting at $399 |
| Wegovy® | Starting at $947 |
| Mounjaro® | Starting at $947 |
| Ozempic® | Starting at $499 |
Read that table carefully, because the page does not lay it out this way. On the storefront the price is printed above the product name, so a card reads "Starting at $947" and then "Wegovy®". Anything that pairs a name with the number that follows it is off by one row, and every figure here was taken from inside its own card rather than from the sequence of the page.
One molecule, two prices, 4.8× apart
Synergy sells the FDA-approved semaglutide product and a compounded copy of the same molecule on the same tab, at $947 and $199. That is a gap of about 4.8 times. Tirzepatide runs the same way at a narrower ratio: Mounjaro at $947 against compounded tirzepatide at $349.
The page offers no account of the difference, and the difference is the entire subject of this site. Wegovy has been through the trials the headline's number comes from. The compounded preparation beside it has been through none, from any seller. Those are not two grades of the same thing at two prices; they are a product with a registered evidence file and a product without one.
The brand rows are not all weight-loss drugs
Three approved products sit on that tab, and only one of them is approved for weight loss.
Wegovy is semaglutide 2.4 mg for weight management, and its program is STEP. STEP 4 (NCT03548987) enrolled 902 people with overweight or obesity, with the primary outcome registered as change in body weight at week 68; STEP 3 (NCT03611582) enrolled 611 and carries the registered title "as Adjunct to Intensive Behavioural Therapy" — the trial pairs the drug with behavioral therapy by design. 9 So for this row, and only this row, "proven" holds — and the same two records refute "fast" and "effortless" in the same breath.
Ozempic is semaglutide for type 2 diabetes. Its program is SUSTAIN, and the registered primary outcomes are HbA1c — SUSTAIN 1 (NCT02054897, n=388) — and major adverse cardiovascular events — SUSTAIN 6 (NCT01720446, n=3,297). 10 Neither trial's primary endpoint is body weight.
Mounjaro is tirzepatide for type 2 diabetes. Its program is SURPASS: SURPASS-2 (NCT03987919, n=1,879) compared it against semaglutide as an add-on to metformin, and SURPASS-1 (NCT03954834, n=478) against placebo, both measuring HbA1c. 11
None of that makes the two diabetes drugs ineffective, and this site does not tell anyone what to take. It makes the headline wrong in a specific way: a percentage from one product's obesity program is printed over two products whose own pivotal trials measured blood sugar, and the cheapest brand row on the tab — Ozempic at $499, about half the others — is the one furthest from the claim above it.
The two tablets have no route evidence at all
The oral dissolving tablets are $299 and $399, which puts the tirzepatide one above every compounded injection on the tab.
ClinicalTrials.gov holds no study of either molecule as an orally dissolving or sublingual tablet. Searched on 26 August 2026 against the intervention field, with no status filter so that a merely planned study would still appear: "sublingual tirzepatide", "orally disintegrating tirzepatide", "orally disintegrating semaglutide" and "buccal semaglutide" each returned zero. "Sublingual semaglutide" returned two records, and neither is one — one is a subcutaneous study, the other an early-phase-1 trial of a "Sublingual GLP1" that is enrolling by invitation and does not name its molecule in the registry. 12 The controls fired in the same pass: tirzepatide 276 records and 91 completed, semaglutide 339 completed, oral semaglutide 197 records.
Oral semaglutide is not the exception it looks like. There is an approved semaglutide tablet — Rybelsus — and a large program behind it, PIONEER 1 (NCT02906930, n=703) among them. 13 But that tablet is swallowed whole, and it works because it is formulated with an absorption enhancer that carries the peptide across the stomach lining. A tablet that dissolves in the mouth is a different dosage form asking a different membrane to do the work. The PIONEER and OASIS results belong to the swallowed tablet, and a compounded ODT is not it.
For tirzepatide there is not even that much: every registered arm in 276 records is a subcutaneous injection. The oral incretin drug in late-stage development, orforglipron, is a small molecule rather than a peptide — a different drug, whose program says nothing about a tirzepatide tablet.
Route is not a packaging choice for peptides this size. It is the question of whether any drug reaches the blood, and for both tablets the registry's answer is that nobody has published one.
Two documents, two companies, three states
Synergy's FAQ does the best thing on the site:
"Who are your Pharmacy Providers? … Belmar Pharmacy | 800-525-9473 | belmarpharmasolutions.com · Strive Pharmacy | 855-405-5993 · Epiq Scripts | 833-654-3553 · Casa Pharma Rx | 877-937-6868"
Plus two named doctors whose licenses you can look up. That is a real disclosure.
Now open the Terms & Conditions — the document a careful buyer would actually read. It names no pharmacy at all. Anyone who checks there concludes this company discloses nothing, which is false. The disclosure exists in exactly one place, and it is not the place with legal force.
The Terms have other problems. They open:
"CAREGLP IS CONTEMPLATED FOR SPECIFIC NON-EMERGENCY MEDICAL CONDITIONS AND CONCERNS."
"CareGLP" appears 68 times in that document; "SynergyRx" appears 56. The agreement is substantially another brand's, lightly adapted. It defines the parties as "CareGLP, owned by SynergyRx, a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609", and venues disputes "exclusively in the U.S. District Court for Georgia, or a state court located in Fulton County, Georgia."
A Delaware corporation, at a Wyoming address, litigating in Georgia.
The document is dated 1 January 2024 and contains zero occurrences of "subscription" and zero of "cancel". A patient buying a recurring medication has no published cancellation terms.
And on coverage, the two documents disagree outright. The FAQ: "Our telemedicine services are available in all 50 U.S. states." The Terms, section V: "The Services are currently available to individuals located in certain states. To see the list of current states, please contact customer service." Neither publishes a list.
What this means if you are buying
The pharmacy list is real and useful: four named facilities with phone numbers, and two doctors whose licenses you can verify. If you buy here, use it — ring the pharmacy and ask for the lot record, because Synergy publishes no certificate of analysis for anything.
On the GLP-1s, the medicine is well evidenced and the headline is not. Expect a 68-week horizon and lifestyle work, not "fast" and "effortless". The prices — $199 semaglutide, $349 tirzepatide, $299 oral — are behind the Weight Loss tab, which the page does not open on.
On the four $275 products, there is no description to read, and the evidence runs from "one null trial in the wrong disease" to "nothing at all". PT-141 is the one with real trials behind it, and those trials were in women, for a condition Synergy does not name.
Before you commit to anything recurring, note that the Terms do not contain the word cancel.
Questions
Frequently asked questions
Does Synergy Rx publish its GLP-1 prices?
Yes — behind a tab the page does not open on. Synergy's products page has category tabs (Longevity, Hair, Sexual Health, Skin, Weight Loss) and defaults to Longevity. One click on Weight Loss shows seven rows, re-read card by card in a browser on 26 August 2026: compounded semaglutide $199, compounded tirzepatide $349, the semaglutide oral dissolving tablet $299, the tirzepatide oral dissolving tablet $399, Wegovy $947, Mounjaro $947 and Ozempic $499. The catch is easy to miss: the page you land on already shows five Longevity products with real prices, so it looks complete, and nothing tells you four more tabs exist. One more trap sits on the cards themselves — the price is printed above the product name, so pairing a name with the number after it shifts every figure by a row.
Do Synergy Rx's oral dissolving tablets work?
Nobody has published an answer, and Synergy does not offer one. It sells a Compounded Semaglutide Oral Dissolving Tablet at $299 and a Compounded Tirzepatide Oral Dissolving Tablet at $399. Searched on 26 August 2026 with no status filter, ClinicalTrials.gov returns no study of either molecule as an orally dissolving or sublingual tablet — "sublingual tirzepatide", "orally disintegrating tirzepatide", "orally disintegrating semaglutide" and "buccal semaglutide" each return zero, while the controls in the same pass return 276 tirzepatide records and 339 completed semaglutide studies. There is an approved semaglutide tablet, Rybelsus, but it is swallowed whole and works through an absorption enhancer that carries the peptide across the stomach lining; a tablet dissolved in the mouth is a different dosage form, and the PIONEER and OASIS results belong to the swallowed one. Synergy publishes no bioavailability figure, no pharmacokinetic result and no study for either tablet.
Are Wegovy, Ozempic and Mounjaro all weight-loss drugs?
Only one of the three is approved for it. Wegovy is semaglutide 2.4 mg for weight management, and its STEP trials measured body weight — STEP 4 (NCT03548987) in 902 people and STEP 3 (NCT03611582) in 611. Ozempic is semaglutide for type 2 diabetes, registered on SUSTAIN, whose primary outcomes are HbA1c (SUSTAIN 1, NCT02054897, 388 participants) and cardiovascular events (SUSTAIN 6, NCT01720446, 3,297). Mounjaro is tirzepatide for type 2 diabetes, registered on SURPASS, also measuring HbA1c (SURPASS-2, NCT03987919, 1,879 participants; SURPASS-1, NCT03954834, 478). All three sit under the same weight-loss headline on Synergy's tab, and the page never mentions that two of them are diabetes drugs. Ozempic is also the cheapest of the three at $499, roughly half the $947 on the other two.
Why does Wegovy cost 4.8 times the compounded semaglutide?
Synergy does not say, and the two sit on the same tab: Wegovy at $947, compounded semaglutide at $199. The difference is not a grade of quality within one product — it is an FDA-approved finished drug with an NDC and a registered evidence file, beside a preparation made by a compounding pharmacy for an individual patient that has never been through a trial from any seller. Mounjaro runs the same comparison at a narrower ratio, $947 against $349 for the compounded tirzepatide injection. This site does not tell anyone which to buy; it reports that only one of each pair is the thing the headline's number was measured in.
Why are four different peptides all $275?
Synergy does not say. NAD+ Injection, Sermorelin Injection, Glutathione Injection and PT-141 are each listed "Starting at $275", with B12 at $109. Those four molecules have nothing in common — a growth-hormone-releasing peptide, a coenzyme, a tripeptide antioxidant and a melanocortin receptor agonist — and their evidence bases range from two phase 1 studies to none at all. Every figure is a "Starting at" floor rather than a price, and Synergy publishes no dose, no supply length and no billing interval for any of them. It also publishes no description of any of them: no mechanism, no indication, no benefit, no contraindication.
Is Synergy Rx's "15% weight loss" claim accurate?
The number is real and everything around it is wrong. Synergy's homepage reads "The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week", under "effortless weight loss". The 15% comes from STEP 1, which reported about 14.9% from baseline against 2.4% on placebo — but that trial tested the approved 2.4 mg product, not a compounded preparation, and Synergy cites nothing anywhere on its site. "Fast" is the opposite of the truth: STEP 1 ran 68 weeks. "Effortless" is contradicted by the trial's design, in which every participant received a reduced-calorie diet, increased activity and monthly counseling — the 15% is what the drug added on top of that effort. "Lose 1-2lbs per week" has no source at all.
Which pharmacy does Synergy Rx use?
It names four in its homepage FAQ, with phone numbers and websites: Belmar Pharmacy (800-525-9473), Strive Pharmacy (855-405-5993), Epiq Scripts (833-654-3553) and Casa Pharma Rx (877-937-6868). It also names two licensed prescribing clinicians — Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD — through Lion MD. That is a genuine disclosure and the best thing on the site. The catch is that it exists in exactly one document: Synergy's Terms & Conditions name no pharmacy at all, so anyone who looks in the legally binding document concludes this company discloses nothing. Which of the four fills a given order is not published.
What do Synergy Rx's terms actually say?
Less about Synergy than you would expect. The agreement is substantially another brand's document: "CareGLP" appears 68 times against 56 for "SynergyRx", and it opens "CAREGLP IS CONTEMPLATED FOR SPECIFIC NON-EMERGENCY MEDICAL CONDITIONS AND CONCERNS". It defines the parties as "CareGLP, owned by SynergyRx, a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609" and venues disputes in Fulton County, Georgia — three states for one company. It is dated 1 January 2024. Most consequentially for a patient buying a recurring medication, it contains zero occurrences of the word "subscription" and zero of the word "cancel", so there are no published cancellation terms. Its section V also says services are available "in certain states", where the homepage FAQ says all 50.
Is PT-141 appropriate for men?
The approved label says it is not, and Synergy does not mention the question. PT-141 is bremelanotide, and its two phase 3 trials — RECONNECT 1 and 2, enrolling 723 and 714 participants — were in premenopausal women with hypoactive sexual desire disorder. The approved product containing the molecule is Vyleesi, whose label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men" and "VYLEESI is not indicated to enhance sexual performance." Synergy lists PT-141 under Sexual Health at $275 with no indication, no population and no reference to either sentence. This site does not tell you what to take; it reports that the evidence is real, and is for a different population and a different purpose than the listing implies.
Glossary
Key terms
Show definitions
- Client-rendered tab
- Page content that appears only after you click a control — it is not on the page as it first loads. It is published information; you simply have to know to click. Synergy's weight-loss prices sit behind one.
- Starting at
- A floor, not a price. It states the lowest figure in a range without committing to a dose, a supply length or a billing interval. All five of Synergy's longevity products are priced this way.
- Limitations of Use
- A section of an FDA-approved label stating what a drug is specifically not indicated for — a boundary on the approval itself rather than a caution. Vyleesi's names men, postmenopausal women and performance enhancement.
- Orally dissolving tablet (ODT)
- A tablet designed to dissolve in the mouth rather than be swallowed, so the drug is absorbed through the lining of the mouth. It is a different dosage form from a swallowed tablet, not a convenience version of one — and for a peptide, a different route means a different question about whether the drug reaches the blood at all.
- Route of administration
- How a drug enters the body — injected under the skin, swallowed, dissolved under the tongue. For large peptides it is the decisive variable: semaglutide and tirzepatide are both destroyed by digestion, which is why the approved injections are injections and the approved semaglutide tablet carries an absorption enhancer. A trial of one route is not evidence for another.
- Approved indication
- The specific condition an FDA approval covers, which is narrower than the molecule. Semaglutide is approved for type 2 diabetes as Ozempic and for weight management as Wegovy, at different doses under different labels and on different trial programs. Tirzepatide is approved for type 2 diabetes as Mounjaro.
- Sermorelin
- A synthetic fragment of growth hormone-releasing hormone, GHRH(1-29). Once approved in the US as Geref; that approval has been withdrawn, and no current ClinicalTrials.gov record names sermorelin as an intervention.
Compare
Others selling what Synergy Rx sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Synergy Rx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 13 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six searches run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. Control searches in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] returns 19 records, published 1986-2005. Restricting the same query to title and abstract returns 0, because the trial literature names the molecule GHRH(1-29)-NH2 rather than sermorelin. Re-run 2026-08-12 with a fabricated-molecule negative control returning 0.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim; zero randomised-controlled-trial publications for nicotinamide adenine dinucleotide combined with injection or subcutaneous administration. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- US National Library of Medicine (2026). Injected glutathione in humans — re-run 2026-08-26 over all interventional glutathione records. Only a small minority involve an injected or intravenous route, and just one of those is completed: NCT00889538, glutathione given as a drug to 24 children with autism. The two records this review previously cited here, NCT01355198 and NCT02348775, are dietary-supplement studies of ORAL precursors (n-acetylcysteine and glycine) and do not administer glutathione at all.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=glutathione
- US National Library of Medicine (2026). RECONNECT Study 1 (NCT02333071, phase 3, completed, n=723) and RECONNECT Study 2 (NCT02338960, phase 3, completed, n=714) — bremelanotide in premenopausal women with hypoactive sexual desire disorder. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02333071
- US Food and Drug Administration (2026). VYLEESI (bremelanotide) injection — prescribing information, section 1, Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." Read 2026-08-10.. FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- US National Library of Medicine (2026). Wegovy's own program, read live from the registry on 2026-08-26. STEP 4 (NCT03548987, phase 3, completed, n=902) — "Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity", primary outcome "Change From Randomisation to Week 68 in Body Weight (%)". STEP 3 (NCT03611582, phase 3, completed, n=611) — the same dose "as Adjunct to Intensive Behavioural Therapy", primary outcome "Change in Body Weight (%)". Conditions on both: overweight and obesity.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03548987
- US National Library of Medicine (2026). Ozempic's own program, read live from the registry on 2026-08-26. SUSTAIN 1 (NCT02054897, phase 3, completed, n=388) — semaglutide once-weekly versus placebo in drug-naive subjects with type 2 diabetes, primary outcome "Change in HbA1c". SUSTAIN 6 (NCT01720446, phase 3, completed, n=3,297) — cardiovascular outcomes in type 2 diabetes, primary outcome time to first major adverse cardiovascular event. Condition on both: type 2 diabetes, not obesity.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02054897
- US National Library of Medicine (2026). Mounjaro's own program, read live from the registry on 2026-08-26. SURPASS-2 (NCT03987919, phase 3, completed, n=1,879) — tirzepatide versus semaglutide once weekly as add-on to metformin in type 2 diabetes, primary outcome change from baseline in HbA1c. SURPASS-1 (NCT03954834, phase 3, completed, n=478) — three tirzepatide doses versus placebo in type 2 diabetes, primary outcome change from baseline in HbA1c, every arm subcutaneous.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03987919
- US National Library of Medicine (2026). Route-of-administration screen for the two oral dissolving tablets, run 2026-08-26 with no status filter. Intervention searches "sublingual tirzepatide", "orally disintegrating tirzepatide", "orally disintegrating semaglutide", "orally disintegrating tablet semaglutide" and "buccal semaglutide" each returned 0 records. "Sublingual semaglutide" returned 2, neither a sublingual semaglutide study: NCT06301191 (subcutaneous semaglutide) and NCT07092605 (early phase 1, enrolling by invitation, a "Sublingual GLP1" whose molecule the registry does not name). Controls in the same pass: tirzepatide 276 records and 91 completed, semaglutide 339 completed, oral semaglutide 197 records, orforglipron 50 records.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sublingual%20tirzepatide
- US National Library of Medicine (2026). PIONEER 1 (NCT02906930, phase 3, completed, n=703) — "Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only", primary outcome "Change in HbA1c", intervention administered orally once daily. The registered evidence for semaglutide by mouth is for a tablet swallowed whole with an absorption enhancer, not for one dissolved in the mouth. Read 2026-08-26.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02906930
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.